Document is current
Any future updates will be listed below
-
Authors
Desai, Kanan T.
Ajenifuja, Kayode O.
Banjo, Adekunbiola
Adepiti, Clement A.
Novetsky, Akiva
Sebag, Cathy
Einstein, Mark H.
Oyinloye, Temitope
Litwin, Tamara R.
Horning, Matt
Olanrewaju, Fatai Olatunde
Oripelaye, Mufutau Muphy
Afolabi, Esther
Odujoko, Oluwole O.
Castle, Philip E.
Antani, Sameer
Wilson, Ben
Hu, Liming
Mehanian, Courosh
Demarco, Maria
Gage, Julia C.
Xue, Zhiyun
Long, Leonard R.
Cheung, Li
Egemen, Didem
Wentzensen, Nicolas
Schiffman, Mark https://orcid.org/0000-0002-4625-2508
- License Information
-
More Information
Article History
Received: 28 July 2020
Accepted: 22 September 2020
First Online: 14 October 2020
Ethics approval and consent to participate
: The study was approved by National Cancer Institute Special Studies Institutional Review Board (NCI-SSIRB) [iRIS reference number: 376424; IRB number: 09CN045; Version date: 12/20/2017] and OAUTHC Ethics and Research Committee (ERC) [Protocol number: ERC/2016/05/08 and ERC/2018/09/10; Registration number international: IRB/IEC/0004553, national: NHREC/27/02/2009a].Written informed consent was take from all the participants.
: N/A
: The HC2 test kits were donated by Qiagen. The OncoE6 test kits were donated by Arborvitae. The MobileODT EVA system devices and data management software were donated by MobileODT. None of the companies had any role in design, analysis, interpretation, and finalization of the manuscript.
